Stabilized erythrocytes and methods therefor
US4136161A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 16, 1976 |
| Grant date | Jan 23, 1979 |
| Priority date | — |
| Expiry date | Mar 16, 1996 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/826
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A double aldehyde treatment process of erythrocytes is disclosed. Erythrocytes from various sources can be treated in a two-step process to render them stable and subsequently useful in antigen antibody detection systems. Glyoxal is used as a first treating medium followed by a second treatment step using formaldehyde or glyoxal as the fixative. Glyoxal is used in the first step in amounts ranging from 0.1 to 0.4 gm. per 0.8 ml. of Packed Cell Volume of erythrocytes, followed by the second treatment step in which at least 0.1 gm. of formaldehyde or glyoxal and preferably 0.1 to 0.6 gm. per 0.8 ml. Packed Cell Volume of treated erythrocytes is used. The reaction medium is preferably aqueous hypertonic and most preferably a sodium citrate medium. The treated cells can be used in detection of hepatitis associated antigen in a reverse passive hemagglutination test.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.